CDSCO Panel Approves Johnson and Johnson's Protocol Amendment Proposal to Study JNJ-77242113
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major Johnson and Johnson's protocol amendment proposal for the drug JNJ-77242113.
This came after the firm presented Protocol Amendment 3 dated 02 April 2024 protocol no. 7242113UCO2001.
JNJ-77242113 or JNJ-2113 stands out as the first oral peptide specifically designed to inhibit the IL-23 receptor. This means it blocks the activity of the IL-23 receptor, which is a protein involved in the immune system's inflammatory processes. Interleukin-23 plays a significant role in the development and progression of plaque psoriasis, a chronic skin condition characterized by red, itchy, and scaly patches. By inhibiting the IL-23 receptor, JNJ-2113 can potentially reduce the inflammation, proliferation, and development of psoriatic plaques, thereby alleviating symptoms associated with moderate-to-severe plaque psoriasis.
The mechanism of action of JNJ-2113, a targeted oral peptide, involves specifically blocking the activity of the interleukin-23 (IL-23) receptor, which plays a critical role in the immune system's inflammatory processes.
At the recent SEC meeting for gastroenterology and hepatology held on June 20, 2024, the expert panel reviewed Protocol Amendment 3 dated 02 April 2024 protocol no. 7242113UCO2001.
After detailed deliberation, the committee recommended the approval of the protocol amendment as presented by the firm.
Also Read: Cipla Gets CDSCO Panel Nod to Study Plazomicin Injection
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.